Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Limited Competition: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Studies (U01 Clinical Trial Not Allowed)" aimed at supporting preclinical research using adult stem cells. This initiative invites current recipients of prior RMIP grants to submit renewal applications that focus on late-stage preclinical studies, enhancing the development of safe and effective regenerative medicine therapies while addressing critical regulatory issues and promoting data sharing. The NIH plans to allocate up to $3.5 million in federal funds, with a requirement for successful applicants to match these funds with non-federal contributions on a 1:1 basis, as mandated by the 21st Century Cures Act. Interested applicants must adhere to specific guidelines and demonstrate significant collaboration with NIH staff, with applications due by October 21, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-25-013.html.
Eligible Applicants
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.